相关实验视频

Updated: May 26, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

来自Physalis minima的抗炎维他诺化物及其对小鼠性结肠炎的治疗潜力

Guozhu Su¹, Lisha Chai¹, Yu Chen²

¹State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.

|February 22, 2025

概括

来自Physalis minima Linn. 的新型维他诺化物. 通过抑制关键信号通路,显示出显著的抗炎作用. 在体内研究证实了它们在治疗性结肠炎方面的潜力,突出了15化合物.

科学领域:

自然产品化学化学
药理学药理学是指药理学的学科.
药用化学医学化学

背景情况:

菲萨利斯最小的线. 是生物活性化合物的植物来源.
维他诺化物是类固醇乳的一类,具有多样化的生物活性.
炎症和性结肠炎是严重的健康问题,需要新的治疗药物.

研究的目的:

从Physalis minima Linn.中分离和描述新的维他诺化物.
评估这些化合物的体外抗炎潜力.
在性结肠炎的临床前模型中评估有前途的化合物的体内疗效.

主要方法:

使用广泛的光谱方法 (NMR,HRESIMS,IR,ECD,X射线晶体学) 进行隔离和结构阐明.
在体外抗炎试验测量核因子kappa-B (NF-κB) 和中白素-6 (IL-6) 信号的抑制.
在硫酸 (DSS) 诱导的性结肠炎小鼠模型中的体内评估.

主要成果:

除了已知的衍生物外,还发现了11种新的维他诺化物 - - 菲米诺化物I-XI.
化合物4-6,13,和15显示显著抑制NF-κB信号传递.
化合物4和13也抑制了IL-6通路的激活.
化合物15在体内显著改善了性结肠炎症状.

结论:

这项研究成功地从Physalis minima Linn.中分离和表征了新型维他诺化物.
这些化合物通过抑制NF-κB和IL-6通路表现出强大的抗炎性质.
化合物15显示了性结肠炎的治疗潜力,需要进一步调查.

关键词:

在IL6/JAK/STAT3中使用.作为NF-kB抑制剂的使用.菲米尼诺化物是什么体 (Physalis minina) 是一个小型的植物.这是Solanaceae.性结肠炎是一种

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...